Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment 2)(Name of Issuer) Catalyst Biosciences, Inc. (Title of Class of Securities) Common Stock (CUSIP Number) 14888D208 (Date of Event Which Requires Filing of this Statement) December 31, 2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]Rule 13d-1(b) [ X ]Rule 13d-1(c) [ ]Rule 13d-1(d) CUSIP No. 14888D208 1.Names of Reporting Persons. Laurence W.Lytton 2. Check the Appropriate Box if a Member of a Group (See Instructions) a).......................................................................... (b).......................................................................... 3.SEC Use Only 4.Citizenship or Place of Organization USA 5.Sole Voting Power 117,000 (1) 6.Shared Voting Power 7.Sole Dispositive Power 117,000 (1) 8.Shared Dispositive Power 9.Aggregate Amount Beneficially Owned by Each Reporting Person 117,000 (1) (1) includes warrants to purchase 37,500 shares at an exercise price of $5.50 per share. 10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)................................. 11.Percent of Class Represented by Amount in Row (9) 1.2% (2) (2) Based on 9,799,347 pro forma shares of common stock outstanding as of February 14, 2018 as indicated in the 424B5 filing dated February 14, 2018. 12.Type of Reporting Person (See Instructions) IN Item 1. (a)Name of Issuer Catalyst Biosciences, Inc. (b)Address of Issuer's Principal Executive Offices 260 Littlefield Ave. South San Francisco, California